NovelStem International Corp. (NSTM) Fair Value 2026

NSTM · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (27/100)

Quick Summary — As of 2026-08-27, NovelStem International Corp. (NSTM) trades at $0.01. QOC: 4.2/10. Value Trap Risk: 27/100 (LOW). 1/13 models active.

Key Facts

Ticker
NSTM
Price
$0.01
Quality Score
4.2/10
Value Trap Risk
27/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.2/10 signals weak fundamentals

What Fair Value Does Each Model Give NSTM?

1 Intrinsic Value Models vs. Current Price ($0.01)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $0.00 -84.4%

All Models Active

All 1 models are displayed above.

What Is NovelStem International Corp. (NSTM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, NovelStem International Corp.'s intrinsic value is estimated at $0.00. Trading at its current price of $0.01, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -84.4%.

What Do the Models Say About NSTM?

1 of 13 models are currently active for NSTM. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does NSTM Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, NSTM ranks #46 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.

The Diagnostics & Research sector introduces analytical considerations specific to healthcare company businesses. For NovelStem International Corp., metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.

Is NSTM a Value Trap?

CirclFi's Value Trap algorithm assigns NSTM a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for NovelStem International Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, NovelStem International Corp. scores 4.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NSTM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NSTM's 1 active models, average confidence is 15%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy NovelStem International Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

PRPHProPhase Labs, Inc.QOC 4.8NDRAENDRA Life Sciences Inc.QOC 4.0FRNMFreenome, Inc.QOC 4.8FUNIHypha Labs, Inc.QOC 3.9ISPCiSpecimen Inc.QOC 4.8QGENQiagen N.V.QOC 3.2IQVIQVIA Holdings Inc.QOC 8.3TWSTTwist Bioscience CorporationQOC 7.4PSNLPersonalis, Inc.QOC 6.4IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: PRPH · NDRA · FRNM · FUNI · ISPC · QGEN · IQV · TWST · PSNL · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to NSTM?

7 companies across all industries closest to NSTM’s Quality of Company score of 4.2/10.

MRAIMarpai, Inc.QOC 4.2IMAQInternational Media Acquisition Corp.QOC 4.2ANVIAnvi Global Holdings, Inc.QOC 4.2ONARONAR Holding CorporationQOC 4.2NVCTNuvectis Pharma, Inc.QOC 4.2SYRESpyre Therapeutics, Inc.QOC 4.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MRAI · IMAQ · ANVI · ONAR · NVCT · SYRE · NVDA

What Else Do Investors Ask About NovelStem International Corp.’s Valuation?

What is NovelStem International Corp.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for NovelStem International Corp. (NSTM). The Quality of Company score is 4.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NSTM overvalued or undervalued right now?

At $0.01, 0 of 1 active models suggest NSTM may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits NovelStem International Corp.'s business model in Diagnostics & Research.

What does a Quality of Company score of 4.2 mean for NSTM?

NovelStem International Corp.'s QOC of 4.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on NSTM?

CirclFi analyzes NSTM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is NSTM a value trap in 2026?

NovelStem International Corp.'s Value Trap score is 27/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns NovelStem International Corp. (NSTM) a Quality of Company score of 4.2/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/NSTM/ · Methodology
Primary sources for this NSTM valuation
  • Financial statements: NovelStem International Corp. 10-K and 10-Q filings on SEC EDGAR (CIK 0000912544) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NSTM as of ; valuations recomputed .